{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T13:47:38Z","timestamp":1783691258829,"version":"3.55.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Avacopan is an oral selective C5a receptor inhibitor. It received FDA approval in October 2021 for use with standard glucocorticoid therapy to treat antineutrophil cytoplasmic antibody-associated vasculitis. However, there are limitations to understanding adverse events (AEs) in clinical practice. In this study, we analyzed AEs related to avacopan by mining the FDA Adverse Event Reporting System (FAERS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Adverse event reports associated with avacopan were retrieved from the FAERS database covering Q1\u20132022 to Q4 2024. After data standardization, reports exclusively involving avacopan were retained. Two disproportionality analysis methods, namely the reporting odds ratio and Bayesian confidence propagation neural network, were utilized to detect safety signals related to avacopan. A semi-quantitative scoring approach was employed to evaluate the clinical priority of the detected signals. Moreover, racial disparities in the occurrence risks of critical adverse event signals as well as temporal patterns of avacopan-related AEs were examined.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 1,128 avacopan-related reports, 33 adverse event signals were identified. These included label-listed AEs (nausea, fatigue, diarrhea, headache, rash, hypertension, blood creatinine increased, and abnormal liver function). Five new potential AEs were detected, including alopecia, increased appetite, hyperaesthesia teeth, oesophageal disorder, and muscle atrophy. Clinically, 0 were classified as high-priority signals, 2 as moderate-priority signals, and 31 as low-priority signals. Compared to American patients, Japanese patients exhibited a higher risk of liver dysfunction (p&amp;lt;0.001), while alopecia occurred exclusively in the American patient population. The median time to AE onset time for avacopan was 86.5 days(interquartile range [IQR] 27-236.75), with most occurring within the first month of treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Avacopan exhibits favorable real-world safety with no high-priority AEs identified. Our findings may provide important evidence for future clinical research and the management of safety issues related to avacopan.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1654735","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T04:18:09Z","timestamp":1759897089000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["The safety profiles of avacopan on microscopic polyangiitis and granulomatosis with polyangiitis: a real-world pharmacovigilance analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Yang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2332\/allergolint.R-07-141","article-title":"ANCA-associated vasculitis: diagnostic and therapeutic strategy","volume":"56","author":"Ozaki","year":"2007","journal-title":"Allergol Int"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/neup.12821","article-title":"Early ultrastructural lesions of anti-neutrophil cytoplasmic antibody- versus complement-associated vasculitis","volume":"42","author":"Koike","year":"2022","journal-title":"Neuropathology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.3390\/jcm14051724","article-title":"Current diagnosis and treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis: A review including a comparison of characteristics in Europe and Japan","volume":"14","author":"Horai","year":"2025","journal-title":"J Clin Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.advms.2020.01.002","article-title":"Treatment and its side effects in ANCA-associated vasculitides - Study based on POLVAS registry data","volume":"65","author":"Biedro\u0144","year":"2020","journal-title":"Adv Med Sci"},{"key":"B5","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s40265-021-01643-6","article-title":"Avacopan: first approval","volume":"82","author":"Lee","year":"2022","journal-title":"Drugs"},{"key":"B6","doi-asserted-by":"publisher","first-page":"6676","DOI":"10.3390\/jcm13226676","article-title":"Role of avacopan on antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis","volume":"13","author":"Sandino","year":"2024","journal-title":"J Clin Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1159\/000543159","article-title":"Practical management of ANCA-associated vasculitis: A clinician\u2019s perspective","volume":"5","author":"Stacey","year":"2024","journal-title":"Glomerular Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016111179","article-title":"Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis","volume":"28","author":"Jayne","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.888816","article-title":"Complement inhibition in ANCA-associated vasculitis","volume":"13","author":"Tesar","year":"2022","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/road081","article-title":"Clinical practice guidelines of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis for the management of microscopic polyangiitis and granulomatosis with polyangiitis: The 2023 update - secondary publication","volume":"34","author":"Sada","year":"2024","journal-title":"Mod Rheumatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaf122","article-title":"Efficacy and safety of avacopan in patients aged 65 years and older with ANCA-associated vasculitis: a post hoc analysis of data from the ADVOCATE trial","volume":"64","author":"Geetha","year":"2025","journal-title":"Rheumatol (Oxford)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11092573","article-title":"Systematic review and metaanalysis of worldwide incidence and prevalence of antineutrophil cytoplasmic antibody (ANCA) associated vasculitis","volume":"11","author":"Redondo-Rodriguez","year":"2022","journal-title":"J Clin Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa089","article-title":"An update on the epidemiology of ANCA-associated vasculitis","volume":"59","author":"Mohammad","year":"2020","journal-title":"Rheumatol (Oxford)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae534","article-title":"The real-world use and effectiveness of avacopan in routine practice for the treatment of ANCA vasculitis. First experiences in Spain","volume":"64","author":"Draibe","year":"2025","journal-title":"Rheumatol (Oxford)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/mrcr\/rxae071","article-title":"Persistent liver injury following avacopan discontinuation in antineutrophil cytoplasmic antibody-associated vasculitis: A rare case of liver biopsy in the chronic phase of liver injury","volume":"9","author":"Yamaguchi","year":"2025","journal-title":"Mod Rheumatol Case Rep"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.15400","article-title":"Case report: Avacopan-induced severe liver injury with prolonged jaundice and lipoprotein X-induced dyslipidemia","volume":"27","author":"Kioi","year":"2024","journal-title":"Int J Rheum Dis"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-024-06376-8","article-title":"A case of rapid avacopan-induced liver injury in pediatric granulomatosis with polyangiitis","volume":"39","author":"Nishino","year":"2024","journal-title":"Pediatr Nephrol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead509","article-title":"Severe prolonged liver abnormality with jaundice during treatment for granulomatosis with polyangiitis with rituximab and avacopan","volume":"63","author":"Kojima","year":"2024","journal-title":"Rheumatol (Oxford)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1186\/s41927-025-00456-4","article-title":"Efficacy and safety of avacopan in antineutrophil cytoplasmic autoantibody-associated vasculitis: a retrospective cohort study in Japan","volume":"9","author":"Tagami","year":"2025","journal-title":"BMC Rheumatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2024.03.022","article-title":"Real-world experience with avacopan in antineutrophil cytoplasmic autoantibody-associated vasculitis","volume":"9","author":"Zonozi","year":"2024","journal-title":"Kidney Int Rep"},{"key":"B23","volume-title":"LiverTox: clinical and research information on drug-induced liver injury","year":"2012"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/mrcr\/rxad019","article-title":"Gradual increase of avacopan dose with concomitant ursodeoxycholic acid use may help avoid the risk of C5a receptor inhibitor-induced liver injury in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"7","author":"Kataoka","year":"2023","journal-title":"Mod Rheumatol Case Rep"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae689","article-title":"Drug-induced liver injury related to avacopan therapy","volume":"64","author":"Mori","year":"2025","journal-title":"Rheumatol (Oxford)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0000000000000877","article-title":"Management of antineutrophil cytoplasmic antibody-associated vasculitis: a changing tide","volume":"32","author":"Krishnan","year":"2023","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224816","article-title":"Efficacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomised trial","volume":"83","author":"Geetha","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.5414\/CN111775","article-title":"Avacopan for ANCA-associated vasculitis: Beyond the 52-week treatment course","author":"Eisinger","year":"2025","journal-title":"Clin Nephrol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/mrcr\/rxaf054","article-title":"Unexpected adverse event caused by avacopan: a case of drug-induced hypersensitivity syndrome in microscopic polyangiitis","volume":"9","author":"Nibu","year":"2025","journal-title":"Mod Rheumatol Case Rep"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfae020","article-title":"Avacopan for ANCA-associated vasculitis with hypoxic pulmonary haemorrhage","volume":"39","author":"Chalkia","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1159\/000542294","article-title":"Results of long-term therapy with a biosimilar of eculizumab in patients with paroxysmal nocturnal hemoglobinuria","volume":"148","author":"Kulagin","year":"2025","journal-title":"Acta Haematol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2024.2432500","article-title":"Avacopan as an add-on therapy for ANCA-associated vasculitis: a pharmacological overview","volume":"17","author":"Tesar","year":"2024","journal-title":"Expert Rev Clin Pharmacol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1389","article-title":"Pharmacokinetic evaluation of the CYP3A4 and CYP2C9 drug-drug interaction of avacopan in 2 open-label studies in healthy participants","volume":"13","author":"Miao","year":"2024","journal-title":"Clin Pharmacol Drug Dev"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1654735\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T04:18:11Z","timestamp":1759897091000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1654735\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":33,"alternative-id":["10.3389\/fimmu.2025.1654735"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1654735","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,8]]},"article-number":"1654735"}}